Rayhan Hashmey, MD
Infectious Disease · Beaumont, TXNPI 1467617597
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $754 of the $1,038 with a category attached, or 72.7%. 7 manufacturers reported payments, led by Shionogi Inc at 50.8% of the total. Reporting peaked in 2022 at $492 and has fallen 78.1% since, to $108 in 2025.
Across 35 payments — averaging $29.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shionogi Inc$527
- Merck$127
- Paratek Pharmaceuticals, Inc.$121
- Cipla USA Inc.$82
- AbbVie$73
- Gilead$65
- plus $44 from 1 others
Across 16 payments — averaging $3063.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$37K
- Viiv Healthcare Company$12K
What the payments were for
- Food & beverage$75473%
- Education$28427%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shionogi Inc | 17 | $527 |
| Merck | 5 | $127 |
| Paratek Pharmaceuticals, Inc. | 3 | $121 |
| Cipla USA Inc. | 2 | $82 |
| AbbVie | 3 | $73 |
| Gilead | 3 | $65 |
| Melinta Therapeutics, LLC | 2 | $44 |
How this compares
$1,038 in reported general payments places this provider in the 60th percentile of 576 infectious disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fosfomycin Tromethamine | 18 | $3,790 |
| Daptomycin | 11 | $2,472 |
| Rifampin | 15 | $1,562 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 11 | $182 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Beaumont
- Elizabeth RaceDallas$1.5M
- Ogechika AlozieEl Paso$834K
- Joseph GatheHouston$695K
- Roy ChemalyHouston$686K
- Cedric SpakFort Worth$427K
- Ben BarnettHouston$424K
- Uriel SandkovskyDallas$320K
- Amar SafdarHouston$284K
- Roger BedimoDallas$269K
- Miguel Sierra-HoffmanVictoria$238K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.